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Synopsis: 
The 5-hydroxytryptamine-2A receptor (5-HT2AR) is a G protein-coupled receptor (GPCR) that is 
implicated in the actions of hallucinogens and represents a major target of atypical antipsychotic agents. 
In addition to its classical signalling though phospholipase C (PLC), the receptor can activate several 
other pathways, including ARF-dependent activation of phospholipase D (PLD), which appears to be 
achieved through a mechanism independent of heterotrimeric G proteins.  We show here that wild-type 
and inactive constructs of PLD1 (but not PLD2) respectively facilitate and inhibit ARF-dependent PLD 
signalling by the 5-HT2AR. Further we demonstrate that PLD1 specifically co-immunoprecipitates with the 
receptor and binds to a distal site in GST-fusion protein constructs of its carboxy-terminal tail that is 
distinct from the ARF interaction site, thereby suggesting the existence of a functional ARF:PLD 
signalling complex directly associated with this receptor. This reveals the spatial co-ordination of an 
important GPCR, transducer and effector into a physical complex that is likely to reinforce the impact of 
receptor activation on a heterotrimeric G protein-independent signaling pathway. Signalling of this 
receptor through such non-canonical pathways may be important to its role in particular disorders. 
Short Title:  PLD signalling complex associated with the 5-HT2AR 
Keywords: 5-HT2A receptor; phospholipase D; signalling complex; ADP-ribosylation factor; co-
immunoprecipitation; GST-fusion protein; schizophrenia. 
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Abbreviations: 5-HT, 5-hydroxytryptamine; ARF, ADP-ribosylation factor; BFA, brefeldin A; BSA, bovine 
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terminal; DMEM, Dulbecco's modified minimum essential medium; dpm, disintegrations per minute; 
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IP, immunoprecipitation; PBS, phosphate-buffered saline; PDBu, phorbol 12,13-dibutyrate; PI, protease 
inhibitor cocktail III, Calbiochem; PKC, protein kinase C; PLA2, phospholipase A2; PLC, phospholipase C; 
PLD, phospholipase D; PrC, Protein C; PtdBut, phosphatidyl butanol; PtdIns(4,5)P2, phosphatidylinositol 
4,5-bisphosphate; SEM, standard error of the mean; tm, transmembrane domain. 
 
 
 
INTRODUCTION 
 
The 5-HT2AR is a G protein-coupled receptor (GPCR) of particular clinical interest due to its reported 
involvement in hallucinogenic and antipsychotic drug activity, thus implicating it as a potential therapeutic 
target for the treatment of various neuropsychiatric disorders, in particular schizophrenia [1].  It is widely 
accepted that the 5-HT2AR signals through the heterotrimeric G proteins, Gq/11, to activate phospholipase 
C (PLC), thereby mobilising Ca2+ and activating protein kinase C (PKC) [2].  The third intracellular loop 
(i3) of the receptor is reported to interact directly with and activate Gαq [3].  
 There is evidence that the 5-HT2AR can also utilise various alternative signalling pathways. These 
include Src (through a route that may involve Gαi/o–associated Gβγ subunits [4]), ERK (through routes 
that are dependent on Src, epidermal growth factor (EGF) receptor transactivation or arrestin; [5-8]), 
phospholipase A2 (PLA2; through routes that may involve Gαi/o–associated Gβγ-mediated ERK activation 
and Gα12/13–mediated p38 activation [9, 10]), JAK2/STAT3 [11], Akt [12], GSK3β [13] and phospholipase 
D (PLD) [14-16].  Some of these pathways show partially distinct pharmacologies and receptor reserves 
in comparison to the classical PLC pathway [4, 9, 17, 18].  The 5-HT2AR, like a number of other GPCRs 
in a variety of cell types, can activate PLD through a route dependent on the small G protein ADP-
Ribosylation Factor (ARF), via a mechanism that may involve direct association of ARF with the GPCR 
[14, 15, 19-21]. Our initial demonstration that certain GPCRs could directly couple to small G proteins 
[14] represents an important example of the developing concept of heterotrimeric G protein-independent 
signalling by GPCRs [22-24]. 
 We have recently shown that the 5-HT2AR specifically interacts with ARF1 but not with ARF6 and that 
residues Asn376-Asn384 of the 5-HT2AR, located at the junction between the 7th transmembrane (tm) 
domain and the carboxy-terminal tail (ct), are critical to ARF1 binding and ARF1-dependent PLD 
activation [15, 16].  This region contains a conserved Asn-Pro-x-x-Tyr motif (residues Asn376-Tyr380), 
previously demonstrated to be involved in enabling ARF-dependent PLD activation [14], ARF1/6 
selectivity [16] and agonist-mediated GPCR internalization [3]. 
 In the present study we further show that PLD can also associate directly with the 5-HT2AR, at a 
location in the ct domain distinct from the ARF1 binding site, suggesting the existence of a 5-
HT2AR:ARF:PLD signalling complex.  This is consistent with reports of PLD binding to the µ-opioid 
receptor [25], mGluR1 metabotropic glutamate receptor [26] and M3 muscarinic receptor (unpublished 
observations) and provides the first information on the site of PLD interaction within a GPCR. 
 
 
EXPERIMENTAL 
 
Cell culture and transfection  
COS7 cells were maintained in culture in Dulbecco's modified minimum essential medium (DMEM; 
Invitrogen) containing 10 % normal calf serum (Harlan) and 100 U/ml penicillin and 100 µg/ml 
streptomycin (Invitrogen).  Cells were grown to 60–80 % confluency and sub-cultured twice weekly.  
Cells were seeded into 12-well plates (PLD and PLC assays) or 75/175cm2 flasks (co-
immunoprecipitation and glutathione S-transferase (GST)-fusion protein studies) and allowed to reach ~ 
60 % confluency (after ~24 h) before transfections were performed, with combinations of cDNAs or 
empty vector where appropriate.  After transfer to DMEM containing 2 % Ultroser G (Pall Biosepra), 
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transfections were carried out using GeneJuice (Merck Chemicals Ltd.) or FuGENE 6 (Roche Applied 
Science) according to the manufacturers’ instructions and cells were used 72 h after transfection. 
 
Plasmids and mutagenesis  
The experiments utilised Protein C epitope-tagged human (h) 5-hydroxytryptamine-2A receptor (PrC-5-
HT2AR; [15]; haemagglutinin (HA) epitope-tagged wild-type ARF1-HA and ARF6-HA (from Julie 
Donaldson, NIH); HA epitope-tagged PLD isoforms and mutants (from Mike Frohman, Stony Brook 
University: wild-type HA-PLD1 and HA-PLD2; catalytically inactive HA-PLD1(Lys898Arg) and HA-
PLD2(Lys758Arg)] and an ARF-selective construct, PLD1(PIM87/Ile870Arg) [27].  The cDNA clone for 
human GTP-resistant negative mutant Gαq(Gln209Leu/Asp277Asn) [28] was obtained from the Missouri 
S&T cDNA Resource Center and those for the mouse (m) GnRHR and negative mutant 
RhoA(Thr19Asn) were from Stuart Sealfon (Mount Sinai School of Medicine) and Gary Bokoch (The 
Scripps Research Institute) respectively.  GST-fusion protein constructs of h5-HT2AR-i3(Ile258-Gly326), -
ct(Asn376-Val471) and –ct(Lys385-Val471) have been described previously [15].  To prepare the 
additional truncated 5-HT2ARct constructs, cDNA sequences encoding residues Asn376-Gln428, 
Asn376-Thr438, Asn376-Cys470 of the wild-type 5-HT2AR were PCR-amplified using appropriate primers 
and Taq polymerase (Promega).  The resulting PCR products were purified using the Wizard DNA clean-
up system (Promega) and sub-cloned into the pGEM-T Easy vector (Promega), prior to sequence 
analysis.  Clones containing the appropriate sequences were digested with BamHI and EcoRI, and the 
inserts sub-cloned into the pGEX-2T vector (GE Healthcare).  Finally the BamHI sites were modified with 
Mung bean nuclease, as previously described [15] and the open reading frame checked by sequence 
analysis. 
 
PLC assays  
All chemicals and reagents were obtained from Sigma unless otherwise indicated. Medium was removed 
from transfected cells and replaced with Earle’s balanced salt solution (EBSS; 0.5 ml; Invitrogen) 
containing HEPES (10 mM, pH 7.5), glucose (0.18 %) and [3H]inositol (0.75 µCi/well; Perkin Elmer 
Biosciences).  After 18 h, the medium was replaced with fresh medium additionally containing bovine 
serum albumin (BSA; 0.2 %).  Cells were pre-incubated for 15 min with lithium chloride (10 mM) prior to 
5-HT addition.  After 30 min (unless otherwise indicated), reactions were terminated by the removal of 
medium and the addition of ice-cold formic acid (1 ml, 10 mM), with plates left on ice for at least 1 h to 
ensure lysis.  [3H]inositol phosphates ([3H]InsP) were separated by anion exchange chromatography as 
previously described [14]. 
 
PLD assays  
Medium was removed from transfected cells in 12-well plates and replaced with DMEM (0.5 ml) 
containing [3H]palmitic acid (1.5 µCi/well; Perkin Elmer Biosciences).  After 18 h, the medium was 
replaced with minimum essential medium (0.5 ml) containing HEPES (25 mM, pH 7.5) and fatty acid-free 
BSA (0.5 %). To allow assessment of the transphosphatidylation activity of PLD, butan-1-ol (30 mM) was 
added to each well, immediately followed by the addition of agonist.  Responses were terminated after 
20 min (unless otherwise stated) by the removal of medium and addition of ice-cold methanol (0.5 
ml/well).  Phospholipids were extracted and [3H]phosphatidyl butanol ([3H]PtdBut) was separated on thin 
layer chromatography plates (LK5D; Whatman) as described previously [14]. For experiments on PLD 
responses in native tissues [14, 29], prefrontal cortex was rapidly removed from male Wistar rats and 
immersed in ice-cold, oxygenated Ca2+-free Krebs-Henseleit buffer additionally containing HEPES (10 
mM, pH 7.4), sodium pyruvate (0.5 mM), glutathione (5 µM), creatine phosphate (2 mM), magnesium 
chloride (5 mM) and sodium kynurenate (1 mM). Minislices (150 x 150 µm) were prepared using a 
McIlwain tissue slicer [30] and resuspended in fresh buffer. After 10 min, the medium was replaced with 
cold oxygenated medium lacking magnesium and kynurenate but with 2 mM calcium chloride and the 
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minislice suspensions were aliquoted into 24-well plates. [3H]palmitic acid was added (1.5 µCi/well) and 
the plates incubated for 3 h at 37 oC under 95% O2:5% CO2 prior to assay and analysis as above. 
 
GST-fusion protein studies  
GST-5-HT2AR-i3(258-326), -ct(376-428), -ct(376-438), -ct(376-470), -ct(376-471), -ct(385-471) 
constructs or empty vector were transformed into BL21-RIL bacterial cells, which were then grown up in 
standard 2x yeast extract/tryptone/NaCl medium with 2 % glucose added.  When the cells had reached 
an A600 of 0.6-0.8 units/ml, fusion protein expression was induced by incubation with 0.5 mM isopropyl-β-
D-thiogalactoside (3 h, 37 °C; Invitrogen).  Cells were harvested by centrifugation (7500 g, 10 min, 4 °C), 
lysed with BugBuster reagent (1 ml/50 ml of original cell suspension, 10 min; Merck) and again 
centrifuged (12,000 g, 25 min, 4 °C).  The bacterial supernatant was then incubated for 30 min at room 
temperature with glutathione-sepharose 4B beads (GE Healthcare; 200 µl 1:1 suspension in phosphate-
buffered saline (PBS) with 1:100 protease inhibitor cocktail set III (PI; Calbiochem)/1 ml supernatant), 
after which the matrix was washed extensively with PBS.  To prepare ARF- and PLD-enriched cellular 
extracts, the medium was removed from flasks of transfected COS7 cells and replaced with 2 ml ice-cold 
extraction buffer (ARF buffer: PBS with 1 mM dithiothreitol, 1 mM sodium orthovanadate, 1:100 PI; PLD 
buffer: 20 mM HEPES pH 7.4, 150 mM NaCl, 20 % glycerol, 1 % CHAPS (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulphonate), 1 % sodium deoxycholate, 1 mM sodium 
orthovanadate, 1:100 PI), after which the flasks were left on ice for 45 min. Prior to centrifugation the 
ARF extracts were homogenised with an Ystral homogeniser (Scientific Industries; setting 3, 15 s). The 
lysates were transferred to eppendorf tubes and centrifuged (12,000 g, 15 min, 4 °C) to remove 
particulate material. The washed GST-fusion protein-bead complexes were then incubated overnight 
(4 °C, with rotation) with ARF1-HA- or HA-PLD1-enriched cellular extracts (200 µl of extract added along 
with 200 µl PBS or extraction buffer as indicated).  In some experiments, extracts and beads were 
incubated for 12 h followed by extensive washing of the beads and a further incubation (12 h) with a 
second extract.  Beads were then washed twice in ice-cold buffer A (PBS containing 20 % glycerol, 1 % 
CHAPS, 1 % sodium deoxycholate, 0.5 mM EDTA) with 1:100 PI, followed by three washes with diluted 
buffer A (1:20 in PBS; 1:100 PI).  Retained proteins were detached from the beads by the addition of 50 
µl Laemmli buffer (2 % sodium dodecyl sulphate, 5 % mercaptoethanol, 20 mM Tris-HCl pH 7.4) and 
heating to 70 °C for 5 min. 
 
Immunoprecipitation studies  
Transfected COS7 cells were serum-deprived for 4 h and washed with Hanks' balanced salt solution (10 
ml; Invitrogen), prior to the addition of IP buffer (HEPES 20 mM pH 7.5, NaCl 150 mM, 20 % glycerol, 1 
% CHAPS, 0.5 % sodium deoxycholate, 1 mM sodium orthovanadate and 1:100 PI; 1 ml/75 cm2 flask).  
After 45 min incubation on ice, extracts were centrifuged at 12,000 g (15 min, 4 °C) to remove particulate 
material and the supernatants were pre-cleared with Protein G-sepharose 4B beads (20 µl of 1:1 
suspension in IP buffer; incubation: 45 min, 4 °C, with rotation).  Samples were briefly centrifuged and 
the supernatants were incubated with primary antibodies (mouse anti-Protein C (PrC) tag; HPC4, Roche 
Applied Bioscience or mouse non-immune IgG) and 20 µl/ml Protein G-sepharose 4B suspension 
(incubation: overnight, 4 °C, with rotation).  Beads were collected by centrifugation and washed three 
times with IP buffer prior to the addition of Laemmli buffer (40 µl/ml of original supernatant). 
 
Western blots 
Using the NuPAGE Surelock Mini-cell system (Invitrogen), samples and original supernatants (to monitor 
input levels) from immunoprecipitation and GST studies were run on 4 - 12 % Bis-Tris gels, which were 
subsequently blotted onto polyvinylidene fluoride membrane (Immobilon-PSQ; Millipore).  Detection 
antibodies used in GST-fusion protein studies were: goat anti-GST (GE Healthcare) used with 
horseradish peroxidase (HRP)-linked donkey anti-goat/sheep IgG (Millipore) and HRP-linked rat 
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monoclonal anti-HA (3F10; Roche).  For co-immunoprecipitation studies, detection antibodies used were 
3F10 and HRP-linked mouse anti-PrC tag (HPC4, Roche).  The binding of HRP-linked antibodies to 
membranes was detected by enhanced chemiluminescence using LumiGLO (Cell Signalling 
Technology). 
 
Ligand binding, cell surface biotinylation and plasma membrane capture  
Serum substitute was removed for 4 h prior to experiments. For membrane ligand binding, cells were 
harvested in ice-cold ketanserin binding buffer (50 mM Tris, 5 mM MgCl2, 1 mM EGTA; pH 7.2) 
supplemented with 1:100 PI and disrupted with an Ystral homogeniser (setting 3, 15 s). Lysates were 
centrifuged (10 min, 2000 g, 4 oC), to pellet nuclear debris.  The supernatants were further centrifuged 
(30 min, 12,000 g, 4 oC) to pellet microsomal membranes, which were washed before resuspension by 
trituration.  Membranes were incubated with 0.8 nM [3H]ketanserin (72.2 Ci/mmol) and a range of 
concentrations of unlabelled ketanserin (0.1-300 nM) for homologous displacement, or 10 µM mianserin 
to determine non-specific binding (60 min, 37 oC).  Binding was quenched with ice-cold buffer and 
membranes pelleted by centrifugation (20 min, 12,000 g, 4 oC).  The supernatant was aspirated and 
[3H]ketanserin bound to the pellet was measured by scintillation counting.  Non-linear curve fitting was 
used to derive Kd and Bmax values (GraphPad Prism 4).  Protein concentrations were determined using 
the Pierce BCA Protein Assay Kit.  
 Cell surface biotinylation was carried out using a membrane-impermeant covalent agent, 
biotinamidocaproic acid 3-sulpho-N-hydroxysuccinimide ester; NHS-sulpho-biotin; Pierce) and the 
capture of solubilised biotinylated proteins on (reversibly binding) monomeric avidin agarose beads, 
following the manufacturers’ protocols [31].  Cells were washed with PBS and then incubated with 1 mM 
NHS-sulpho-biotin in PBS (2 h, 4 oC), before its removal and quenching with glycine (75 mM) in PBS (10 
min, 4 oC). After washing in PBS, cells were solubilised in 1 % CHAPS, 0.5 % sodium deoxycholate, 
1:100 PI, PBS with 10 % glycerol). Following centrifugation (20 min, 12,000 g, 4 oC) aliquots of the 
supernatant were incubated with monomeric avidin agarose beads (1 h, 4 oC) with rolling, to bind biotin.  
The beads were then washed before biotinylated proteins were eluted using 2 mM biotin in PBS (30 min, 
4 oC) with rolling.  Total and biotinylated receptor levels were assessed by incubating aliquots of lysate 
and avidin agarose eluate respectively with 0.8 nM [3H]ketanserin and 10 µM mianserin to determine 
non-specific binding as described above.  Binding was terminated by protein precipitation through the 
addition of 18 % polyethylene glycol-8000 in PBS at 4 oC with 0.003 % bovine γ-globulin as a carrier.  
After vigorous vortexing, tubes were kept on ice for 15 min before centrifugation (20 min, 12,000 g, 4 oC). 
[3H]ketanserin associated with the pellets was measured by scintillation counting.  
For plasma membrane isolation prior to co-immunoprecipitation we utilised a recent method [32] 
for selective capture using biotinylated lectin (Concanavalin A-biotin, Acris antibodies GmbH) 
immobilised on Streptavidin-conjugated T1-Dynabeads (Invitrogen) and prepared according to the 
manufacturers’ instructions. COS7 cells expressing PrC-5-HT2AR and HA-PLD1 were homogenised in 
ice-cold ketanserin binding buffer with protease inhibitors (20 strokes mid-speed teflon-glass 
homogeniser) and centrifuged (12,000g, 15 min, 4 oC). Pellets were resuspended in fresh buffer and 
incubated with derivatised beads (75 min, 4 oC, with rolling). Beads with attached membranes were 
captured by magnet and unassociated membranes were kept on ice. Beads were extensively washed 
(six times) with Tris-buffered saline and the associated membranes were then eluted and solubilised by 
three 10 min incubations (4 oC, with rolling) in HEPES (50 mM, pH 7.4) with glycerol (10 %), α-methyl 
mannoside (0.25 M), 1:100 PI, sodium fluoride (1 mM), sodium orthovanadate (1 mM), CHAPS (1 %), 
sodium deoxycholate (0.5 %). Unbound, flow-through membranes were incubated for 30 min with rolling 
in the same buffer. Samples were then centrifuged (100,000 g, 60 min, 4  oC) before aliquots of 
supernatant were incubated with mouse monoclonal anti-HA (clone 12CA5, Roche, 3 µg/ml) or non-
immune IgG (3h, 4 oC, with rolling) and then addition of Protein G-sepharose 4B (50 µl, 50% 
suspension/ml) for a further 1h. Beads were collected and washed twice by centrifugation in Tris-
buffered saline with glycerol (10%). CHAPS (1%) and sodium deoxycholate (0.5%) and then once in 
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ketanserin binding buffer with glycerol (10%) before resuspension in the latter and aliquoting into the 
[3H]ketanserin binding assay (as above). 
 
Data analysis  
For PLC and PLD assays, data are presented as mean values ± the standard error of the mean (SEM), 
from between 6 to 8 separate determinations. In GST-fusion protein studies, densitometric analysis of 
western blot films was performed using Image J software (NIH).  Statistical significance was determined 
by non-parametric tests to avoid  assumptions about normal distribution of the data, using the Friedman 
test with Dunn’s post-hoc analysis or the Wilcoxon test (as appropriate), with p < 0.05 as the criterion for 
significance (GraphPad Prism 4). 
 
 
RESULTS 
 
5-HT2AR-mediated PLD activation primarily involves PLD1  
The contribution of specific PLD isoforms to 5-HT2AR-mediated PLD activation was initially determined in 
time-course studies, using COS7 cells transfected with PrC-5-HT2AR and either wild-type PLD (HA-PLD1 
or -PLD2), catalytically inactive PLD (HA-PLD1(Lys898Arg) or -PLD2(Lys758Arg)) or empty vector.  
Receptor stimulation with 5-HT (3 µM) produced a rapid increase in [3H]PtdBut production with almost 
complete desensitisation observed within 10 min (Fig 1a, b), whereas 5-HT-stimulated PLC activation 
showed little desensitisation for up to 60 min [16].  Following receptor co-expression with wild-type PLD 
isoforms, a significant potentiation of [3H]PtdBut production was observed at all time points with PLD1 
only, with a maximum response at 10 min (7.67 ± 0.57 fold of basal) of more than double control values 
(3.41 ± 0.25 fold of basal; Fig. 1a; p < 0.05, Friedman and Wilcoxon tests, n = 8). Correspondingly, upon 
expression of catalytically inactive mutant PLD isoforms, only the PLD1 mutant altered 5-HT2AR-
mediated PLD activation, with a significant reduction in [3H]PtdBut production observed at all time points 
relative to control (mean maximum response reduced by 86 %; Fig. 1b; p < 0.05, Friedman and 
Wilcoxon tests, n = 8). Neither wild-type nor mutant PLD isoforms had any significant effect on agonist-
stimulated [3H]InsP production at 60 min (Fig. 1c) or at earlier time points (data not shown).  To 
investigate 5-HT2AR-mediated PLD activation in native tissues, minislices of prefrontal cortex were 
rapidly prepared in cold, oxygenated, protective medium and resuspended in modified Krebs-Henseleit 
buffer for labelling with [3H]palmitate prior to assay. Fig. 1d shows that the increase in [3H]PtdBut 
production induced by the selective 5-HT2R agonist (R)-2,5-dimethoxy-4-iodoamphetamine ((R)-DOI 
[33]; 1 µM, 20 min) was inhibited by 67% (p<0.05, n=5) in the presence of the highly selective 5-HT2A R 
antagonist M100907 (MDL; [34]; Axon Medchem; 0.5 µM with 10 min pre-incubation) indicating that the 
major part of the response was 5-HT2AR-mediated.  The response to (R)-DOI was also significantly 
inhibited (by 78%) by the selective PLD1 inhibitor VU 0155069 (VU; [35]; Enzo Life Sciences; 0.5 µM) 
but not by the selective PLD2 inhibitor BML 280 (BML; [36]; Enzo; 5 µM), matching the PLD1 selectivity 
shown by the 5-HT2AR in our cell model system.  
 
The mechanism of 5-HT2AR-mediated PLD activation in the presence or absence of additional 
PLD1 primarily involves ARF rather than alternative pathways  
We have previously demonstrated that 5-HT2AR-mediated PLD but not PLC activation is specifically 
inhibited by dominant negative ARF1 but not ARF6 [15, 16].  However, as the 5-HT2AR is well known to 
couple through Gαq/11 to PLC activation we investigated whether its activation of PLD might be in part 
downstream of this pathway.  Table 1 shows that PLD responses mediated by the 5-HT2AR or those 
amplified by co-transfection of additional PLD1 showed no significant attenuation in the presence of the 
GTP-insensitive negative mutant Gαq(Gln209Leu/Asp277Asn) [28], whereas in contrast, PLD responses 
of the GnRHR (a receptor that substantially utilises Gαq/11-dependent pathways of PLD activation [14]) 
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were strongly attenuated (p < 0.05, Wilcoxon test, n = 6).  Correspondingly, 5-HT2AR-mediated PLD 
activation in the absence or presence of additional PLD1 was unaltered by the PLC inhibitor U73122 
(Table 2a). As PLD activation by some GPCRs may involve tyrosine kinases and the 5-HT2AR is known 
to activate Src [4, 37] we also investigated a number of tyrosine kinase inhibitors. However, agents 
selective for Src-family kinases (PP1, PP2, Src-inhibitor 1; Tocris Bioscience) and an inactive control 
(PP3; [38, 39] were without effect on 5-HT2AR-mediated PLD responses in the absence or presence of 
additional PLD1, as were broader spectrum tyrosine kinase inhibitors, AG 213 and genistein (Table 
2a,b).     
 Further experiments were carried out to investigate the extent of involvement of other prominent 
activators of PLD1, PKC and small G proteins of the ARF and Rho families [40]. Selective inhibitors of 
PKC, bisindolylmaleimide 1 (BIM-1) and CGP 41251 were also shown to have no significant effect on 5-
HT2AR-mediated PLD activation, as were the Gαi/o inhibitor, pertussis toxin and the inhibitor of G protein 
βγ subunit-dependent signalling, gallein (Tocris Bioscience) [41] (Table 2c). Additionally, we used a 
dominant negative construct approach to assess whether RhoA (which can activate PLD1 by direct 
interaction with its carboxy-terminal domain [27] was playing a significant role here. The inactive, GTP-
exchange deficient mutant, RhoA (Thr19Asn) was without significant effect on 5-HT2AR-mediated PLD 
activation despite clearly inhibiting PLD responses of the thrombin receptor (an Asp-Pro-x-x-Tyr, 
receptor with apparently ARF-independent PLD activation [14]; Table 3). 
 A mutant PLD1 construct has been reported in which sequence deletion and mutation abrogate its 
activation by PKC or RhoA but activation of the enzyme by ARF is spared [27]. Table 4 shows that co-
transfection of this ARF-activation-specific mutant of PLD1, PLD1(PIM87/Ile870Arg) with the 5-HT2AR 
caused marked and significant amplification of the PLD response to 5-HT (3 µM; p < 0.05, Wilcoxon test) 
that was not significantly different to that achieved by wild-type PLD1.  As a control, we examined 
phorbol ester-induced activation of PLD (since PLD1 activation by PKC is prevented in the 
PLD1(PIM87/Ile870Arg) mutant).  Phorbol 12,13-dibutyrate (PDBu)-induced PLD responses were 
significantly facilitated by co-transfection of wild-type PLD1 but not PLD1(PIM87/Ile870Arg) (p < 0.05, 
Wilcoxon test, n = 6).  This evidence for ARF-dependence of PLD1 activation by the 5-HT2AR is fully 
consistent with previous data with negative mutant ARF1 [15, 16].  
 
PLD1 co-immunoprecipitates with the 5-HT2AR in a complex primarily of plasma membrane origin  
To investigate the possibility of direct PLD1 interaction with the 5-HT2AR, their co-immunoprecipitation 
was investigated in COS7 cells expressing PrC-5-HT2AR and HA-PLD1. PLD1 was specifically 
associated with PrC tag-directed pulldowns but not non-immune IgG controls (Fig. 2a, bottom panel). 
Similar results were obtained in four further independent experiments. Input levels of PLD1 (Fig. 2a, 
upper panel) and immunoprecipitated receptor (Fig. 2a, middle panel) were monitored. Pilot experiments 
with PLD2 showed no specific association with PrC-5-HT2AR but a degree of non-specific binding (data 
not shown). The time-course of PLD1 co-immunoprecipitation with the 5-HT2AR was investigated through 
incubation with 5-HT (10 µM) from 5 - 60 min but no statistically significant changes were detected (n = 
6). 
 Specific binding of [3H]ketanserin to the PrC-5-HT2AR was assessed by homologous displacement, 
with non-linear curve fitting revealing an affinity (Kd) of 0.58 ± 0.05 nM and number of binding sites (Bmax) 
of 0.90 ± 0.06 pmol/mg protein, n = 4).  To confirm that the PrC-5-HT2AR mediating PLD responses was 
substantially expressed at the cell surface we used a previously described protocol [15, 31] involving cell 
surface biotinylation, solubilisation, capture and elution from monomeric avidin beads, then 
[3H]ketanserin binding to the recovered solubilised receptor, which revealed that 36.3 ± 8.6 % of the 
receptors were labelled and recovered in this way (n = 5).  
 In addition we utilised a recently described method involving avidin-conjugated magnetic beads 
derivatised with biotinylated concanavalin A [32] to capture plasma membrane from COS7 cells 
expressing PrC-5-HT2AR and HA-PLD1, prior to solubilisation, followed by HA tag-directed 
immunoprecipitation and assessment of specific [3H]ketanserin binding to the pulldowns. Over 72% of 
 8 
the specific [3H]ketanserin binding associated with HA-pulldowns in excess of non-immune IgG controls 
was recovered from the captured plasma membrane fraction rather than the (non-plasma membrane) 
flow-through (Fig. 2b). 
 
PLD1 binds to the 5-HT2AR C-terminal tail, at a location distal to the ARF interaction site 
The interaction of PLD1 with specific regions of the 5-HT2AR was then examined using GST-fusion 
protein constructs comprising sections of the receptor C-terminal tail; full-length -ct(376-471), truncated -
ct(385-471) and i3, -i3(258-326) sequences.  Following incubation with glutathione-sepharose beads, the 
bead-GST construct complexes were incubated with COS7 cell extracts enriched in HA-PLD1. 
Association of HA-PLD1 with the constructs was examined by HA immunoblot (Fig. 2c) and quantified 
using densitometry.  Input levels of the GST-5-HT2ARi3, -5-HT2ARct constructs and GST alone were 
similar, as shown by examining GST immunoreactivity (Fig. 2c, lower panel).  Relative to the -ct(376-
471), PLD1 association with the ct(385-471) construct was clearly increased. PLD1 association with the 
i3(258-326) construct was minimal. PLD1 showed no discernible association with GST alone (Fig. 2c). 
Relative intensities of HA-PLD1 binding (ratio bound by construct to GST alone) to the -ct(376-471), -
ct(385-471) and -i3(258-326) constructs were 7.1, 11.5 and 3.4.  PLD1 binding to the –ct(385-471) 
construct was significantly greater than to the complete –ct(376-471) construct and that to the –i3 (258-
326) construct was significantly less (p < 0.05, Wilcoxon test, n = 5).  In contrast, ARF1-HA associated 
more robustly with the full length -ct(376-471) construct than the proximally-truncated form or the i3 
construct [15]. 
 
C-terminally truncated 5-HT2ARct constructs show reduced interaction with PLD1 but not ARF1  
To further delineate regions of the 5-HT2AR carboxy-terminal tail that are important for specific PLD 
association, a series of GST-5-HT2ARct constructs of varying length were examined for their ability to 
bind HA-PLD1 and ARF1-HA.  Full length GST-5-HT2ARct(376-471) and carboxy-terminally truncated -
ct(376-470), -ct(376-438) and -ct(376-428) constructs were captured on glutathione-sepharose beads 
and incubated with HA-PLD1 or ARF1-HA-enriched cellular extracts.  HA-tagged proteins bound to the 
GST constructs were separated by Western blot and the extent of their binding was quantified by 
densitometric analysis (Fig. 3). Both HA-PLD1 and ARF1-HA displayed robust interactions with the full 
length -ct(376-471) construct.  Removal of carboxy-terminal residues from the GST-5-HT2ARct resulted 
in the clear attenuation of HA-PLD1 interaction, with HA-PLD1 immunoreactivity significantly reduced 
with the -ct(376-438) and -ct(376-428) constructs relative to the full length 5-HT2ARct (p < 0.05, Wilcoxon 
test, n = 5).  Following removal of only Val471, at the extreme caboxy-terminus, a small (but not 
significant) reduction in the degree of HA-PLD1 binding was observed. In contrast, carboxy-terminal 
truncation of the 5-HT2ARct(376-471) construct had no significant effect on the level of associated ARF1-
HA immunoreactivity (Wilcoxon test, n = 6). 
 
HA-PLD1 and ARF1-HA separately associate with the 5-HT2ARct  
As both HA-PLD1 and ARF1-HA primarily associated with the 5-HT2ARct domain, the possibility of 
interdependence in their binding was assessed.  Following capture on glutathione-sepharose beads, the 
full length GST-5-HT2ARct(376-471) construct was incubated for two successive 12 h periods with paired 
combinations selected from HA-PLD1, ARF1-HA, ARF buffer and PLD buffer (Fig. 4).  The initial 
association of HA-PLD1 with the GST-5-HT2ARct(376-471) construct did not alter subsequent binding of 
ARF1-HA to the receptor ct construct and similarly, the degree of HA-PLD1 binding to this construct was 
not changed by prior binding of ARF1-HA.  Furthermore, it was clear in both cases that the binding of the 
second protein did not cause displacement of the previously bound protein. This experiment provided no 
evidence to suggest that interactions of ARF1 and PLD1 with the 5-HT2ARct domain were either 
competitive nor co-dependent but should be interpreted with a degree of caution as it did not test the 
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kinetics of simultaneous binding of ARF1 and PLD1 and further, there may be an excess of available 
binding sites for the two ligands on individual GST-ct molecules. 
 
 
DISCUSSION 
 
PLD1 interaction with the 5-HT2AR and mediation of its signalling output  
In earlier studies [15, 16] we showed that the small G protein ARF, in particular the ARF1 isoform, docks 
directly to the proximal ct domain of the 5-HT2AR and plays an important role in PLD activation by the 
receptor.  We now show that PLD, in particular the PLD1 isoform, can also associate with the 5-HT2AR ct 
domain, but in this case to a more distal region.  The current findings provide evidence for the existence 
of a putative signalling complex containing the core elements 5-HT2AR, ARF and PLD. In functional 
signalling experiments, 5-HT-induced PLD responses of the 5-HT2AR were selectively facilitated by 
transfection of additional PLD1 but not PLD2, and correspondingly were selectively inhibited by negative 
mutant (catalytically inactive) PLD1 but not PLD2, while none of the transfections modified PLC 
responses.  These data suggest that PLD1 is the isoform predominantly involved in PLD responses of 
the 5-HT2AR expressed in COS7 cells. Corresponding experiments in prefrontal cortex with new selective 
inhibitors of PLD1 and PLD2 indicated a similarly preferential coupling to PLD1 by the 5-HT2AR in vivo. In 
cellular assays, these agents are reported to show IC50 values for PLD1 and PLD2 respectively of 11 nM 
and 90 nM with more than 160 fold and 20 fold selectivity for their preferred targets [35, 36]. Their use 
here at approximately 50 times the IC50 values in each case should have been adequate to reveal any 
role of either isozyme, given that their absolute potencies in mammalian tissues may not be identical to 
the values reported. We further explored whether any other pathways in addition to ARF contributed to 
these PLD responses. Earlier findings showed effective inhibition of PLD responses by negative mutant 
ARF1 and the ARF-GTP exchange factor inhibitor brefeldin A (BFA) [15]. Here, we demonstrated that 
PLD responses of the 5-HT2AR alone or in the presence of additional PLD1 were apparently independent 
of Gαq/11, Gαi/o, Gβγ subunits, PLC, PKC, Src-family or other tyrosine kinases and RhoA. In addition, a 
mutant form of PLD1 with disrupted activation by PKC or RhoA (but maintained sensitivity to ARF) was 
able to amplify 5-HT2AR PLD responses to an extent comparable to that demonstrated by wild type 
PLD1. Although all pharmacological agents may have effects in addition to those at their primary targets, 
combined experiments with a range of different pharmacological and molecular tools implicate ARF1 but 
not other pathways in 5-HT2AR coupling to PLD activation under the present conditions. 
    Matching the results of the signalling studies, co-immunoprecipitation experiments revealed specific 
association of PLD1 with the 5-HT2AR. The receptor-associated PLD1 appeared to originate largely from 
the plasma membrane, consistent with evidence for its plasma membrane localization and/or stimulus-
induced trafficking in PC12, chromaffin and COS7 cells [31, 42, 43]. This is in contrast to results with the 
µ-opioid receptor [25] and the mGluR1 metabotropic glutamate receptor [26] where specific PLD2 
interaction was reported, and is distinct from our findings with the M3 muscarinic receptor where both 
PLD1 and PLD2 interact to a similar extent (unpublished observations).  The differential selectivity 
shown by these receptors is likely to be due to sequence differences in the putative interaction site, 
which has been localised in the case of the 5-HT2AR to the distal part of the ct domain. PLD2 interaction 
may have a role in endocytosis [25, 26, 44, 45], whereas PLD1 may be important in intracellular 
trafficking as well as signalling [31, 46, 47].  In this study we found that agonist incubation produced no 
significant change in PLD1 co-immunoprecipitation with the 5-HT2AR, at a time when ARF1 association 
was significantly increased [15].  This is consistent with our further data, which were unable to detect 
either competition or co-operativity between ARF and PLD binding to the 5-HT2AR; observations 
contrasting with those at the µ-opioid receptor where ARF facilitated PLD2 interaction [25].  Further 
support for the idea of independent interaction of ARF1 and PLD1 with the 5-HT2AR comes from 
experiments with truncated GST-fusion protein constructs of the 5-HT2ARct domain, which showed the 
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ARF1 interaction site to be in the proximal region (376-384) whereas the PLD1 docking site is 
predominantly more distal (439-471). 
 Interestingly, phosphatidylinositol 4-phosphate 5-kinases (PtdIns4P-5Ks), which are important in 
cellular phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) synthesis, can be directly activated not 
only by ARFs but in addition, by the PLD product phosphatidic acid [48, 49] so might be activated during 
5-HT2AR signalling through ARF1 or its downstream target, PLD1. As PtdIns(4,5)P2 is an essential 
cofactor for PLD1, co-ordinated enhancement of PtdIns4P-5K activity could be important in relaying or 
amplifying signals from the 5-HT2AR to PLD1 via ARF1. Whether PtdIns4P-5Ks might physically 
associate together with ARF and PLD in complexes with the 5-HT2AR is unknown. 
    In summary, we have provided evidence for a novel partnership between the ct domain of the 5-HT2AR 
and PLD1, which in view of our previous demonstration that the PLD activator ARF is also docked to a 
different location within the 5-HT2ARct, suggests the possible presence of a functional 5-HT2AR:ARF:PLD 
signalling complex. This complex would provide the spatial organization to secure robust PLD signaling 
by the 5-HT2AR and focus its impact on downstream targets localised in the immediate vicinity of the 
receptor. Such non-canonical signaling pathways operated by the 5-HT2AR in neurons may play a part in 
mediating its psychotropic influence within the central nervous system. The present findings further 
emphasize the idea that certain GPCRs are able to signal through heterotrimeric G protein-independent 
pathways that may involve direct association of novel transducers and indeed also effector enzymes in 
functional signalling complexes with these receptors. 
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TABLES AND FIGURES 
 
Table 1   Negative mutant Gαq does not inhibit PLD responses of the 5-HT2AR but does inhibit 
those of a control receptor with substantial Gαq/11-dependent PLD activation, the GnRHR.  
Receptor Agonist-induced [3H]PtdBut production 
(fold increment over unstimulated control) 
Empty vector Gαq(Gln209Leu/ 
Asp277Asn) plus 
empty vector 
PLD1 plus 
empty vector 
PLD1 plus 
Gαq (Gln209Leu/ 
Asp277Asn) 
h5-HT2AR 2.13 ± 0.23 1.90 ± 0.22 7.12 ± 1.46* 5.76 ± 0.56* 
mGnRHR 3.38 ± 0.45 0.98 ± 0.12✝ 8.83 ± 1.11* 3.84 ± 0.53✝ 
PLD responses to 3 µM 5-HT or 300 nM GnRH were measured in COS7 cells transfected with 5-
HT2AR or GnRHR, in the presence or absence of PLD1 and Gαq(Gln209Leu/Asp277Asn) or empty 
vector (pcDNA3.1).  * Indicates response significantly greater than that in the absence of additional 
PLD1 and † indicates response significantly less than that in the absence of 
Gαq(Gln209Leu/Asp277Asn) (p < 0.05, Wilcoxon test, n = 8). 
 
Table 2   Lack of effect of a range of signalling pathway inhibitors on 5-HT-induced PLD 
responses of 5-HT2AR-expressing cells.  
Condition 5-HT (3 µM) – induced [3H]PtdBut production 
(fold increment over unstimulated control) 
5-HT2AR plus empty vector 5-HT2AR plus PLD1 
a) control 
U73122 (20 µM) 
AG213 (100 µM) 
Genistein (80 µM) 
2.43 ± 0.26 
3.11 ± 0.48 
3.01 ± 0.33 
2.31 ± 0.40 
4.91 ± 0.53 
5.40 ± 0.69 
5.12 ± 0.78 
4.81 ±0.66 
b) control  
PP1 (10 µM) 
PP2 (5 µM) 
PP3 (5 µM) 
Src-inhibitor1 (20 µM) 
2.83 ± 0.36 
2.53 ± 0.21 
2.40 ± 0.33 
2.71 ± 0.34 
3.01 ± 0.37 
 
6.12 ± 0.72 
5.55 ± 0.70 
5.78 ± 0.41 
5.99 ± 0.60 
5.40 ± 0.63 
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c) control 
BIM-1 (3 µM) 
CGP 41251 (3 µM) 
Pertussis toxin (200 ng/ml) 
Gallein (10 µM) 
2.95 ± 0.33 
3.24 ± 0.39 
2.53 ± 0.61 
3.06 ± 0.44 
2.70 ± 0.31 
6.82 ± 0.83 
6.13 ± 0.91 
7.01 ± 0.53 
6.19 ± 0.71 
6.21 ± 0.65 
PLD responses to 3 µM 5-HT were measured in COS7 cells transfected with 5-HT2AR and empty 
vector (pcDNA3.1) or additional wild-type PLD1. In the case of pertussis toxin, cells were pre-
incubated for 16h. No significant differences from corresponding control responses were detected by 
Wilcoxon test, n=6. a), b) and c) denote different experimental series. 
 
Table 3   Negative mutant RhoA does not inhibit 5-HT-induced PLD responses in 5-HT2AR-
expressing cells but does inhibit responses mediated by the native thrombin receptor.  
Agonist 
 
 
Agonist – induced [3H]PtdBut production 
(fold increment over unstimulated control) 
 
Empty vector Empty vector plus 
RhoA(Thr19Asn) 
PLD1 plus 
empty vector 
PLD1 plus 
RhoA(Thr19Asn) 
5-HT (3 µM) 2.63 ± 0.35 2.72 ± 0.28 5.68 ± 0.97 
 
5.33 ± 0.69 
Thrombin 
(0.5 U/ml) 
3.13 ± 0.42 2.38 ± 0.39 4.72 ± 0.51   2.58 ± 0.37* 
PLD responses to 3 µM 5-HT or 0.5 U/ml thrombin were measured in COS7 cells transfected with 5-
HT2AR and empty vector (pcDNA3.1) or wild-type PLD1 in the absence or presence of 
RhoA(Thr19Asn). * Indicates response significantly different from corresponding response in the 
absence of RhoA(Thr19Asn), p < 0.05, Wilcoxon test, n=6.  
 
Table 4   Amplification of 5-HT-induced PLD responses in 5-HT2AR-expressing cells by 
additional wild type PLD1 is mimicked by a RhoA/PKC–unresponsive, ARF-selective, PLD1 
construct. 
Activator Activator-induced [3H]PtdBut production 
(fold increment over unstimulated control) 
Empty vector PLD1 PLD1(PIM87/Ile870Arg) 
5-HT (3 µM) 1.85 ± 0.10 6.08 ± 0.58* 5.27 ± 0.67* 
PDBu (300 nM) 4.64 ± 0.42 9.79 ± 0.88* 3.93 ± 0.48✝ 
PLD responses to 3 µM 5-HT or 300 nM phorbol 12,13-dibutyrate (PDBu) were measured in COS7 
cells transfected with 5-HT2AR and empty vector (pcDNA3.1), wild type PLD1 or 
PLD1(PIM87/Ile870Arg).  * Indicates response significantly greater than that in the presence of 
pcDNA3.1 and † indicates response significantly less than that in the presence of wild type PLD1 (p < 
0.05, Wilcoxon test, n=6-8). 
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Figure 1  5-HT2AR-mediated PLD activation in COS7 cells and prefrontal cortex predominantly 
involves the PLD1 isoform  
[3H]PtdBut production in response to 5-HT2AR activation was determined in COS7 cells transfected 
with the 5-HT2AR receptor and either a PLD construct or empty vector, (a)-(c) or in prefrontal cortex 
minislices, (d).  Data shown are mean values ± SEM (n=5-8).  (a) 5-HT-induced [3H]PtdBut production 
in COS7 cells expressing PrC-5-HT2AR and either HA-PLD1 (■), HA-PLD2 (▼) or empty vector (●).  A 
significant increase in PLD activation was observed at all time points following PLD1 expression only 
(*p < 0.05, Friedman and Wilcoxon tests), with PLD2 having no discernible effect. (b) 5-HT-induced 
[3H]PtdBut production in COS7 cells expressing PrC-5-HT2AR and either the catalytically inactive 
mutants HA-PLD1(Lys898Arg) (£), HA-PLD2(Lys758Arg) (s) or empty vector (●). A significant 
reduction in PLD activity was observed at all time points following mutant PLD1 expression only (* p < 
0.05, Friedman and Wilcoxon tests), with mutant PLD2 having no discernible effect. (c) Neither wild 
type nor mutant PLD isoforms altered 5-HT-induced PLC activation (d) In prefrontal cortex minislices, 
[3H]PtdBut production induced by the selective 5-HT2R agonist (R)-DOI (3 µM) was inhibited by the 
highly selective 5-HT2AR antagonist M100907 (MDL; 0.5 µM) and by the selective PLD1 inhibitor VU 
0155069 (VU; 0.5 µM) but not by the selective PLD2 inhibitor BML 280 (BML; 5 µM). ( p<0.05, 
Wilcoxon test, n=5). 
 
Figure 2   PLD1 directly associates with the 5-HT2AR in plasma membranes at a site in its 
carboxy-terminal domain  
COS7 cells were co-transfected with PrC-5-HT2AR and HA-PLD1 for immunoprecipitation experiments.  
(a) Anti-PrC antibody (or non-immune IgG; NI IgG) was used to pull-down PrC-5-HT2AR from cell 
lysates, with levels of HA-PLD1 input, immunoprecipitated 5-HT2AR and co-immunoprecipitated HA-
PLD1 shown in the upper, middle and lower panels. The middle and lower panels show corresponding 
lanes from an individual gel probed for PrC or HA tag. The upper panel (HA-PLD1 input) represents 
other lanes from the same gel. HA-PLD1 clearly associated with the immunoprecipitated receptor, with 
minimal interaction observed in the non-immune controls (results typical of 5 separate experiments).  
(b) In COS7 cells co-transfected with PrC-5-HT2AR and HA-PLD1, a plasma membrane fraction was 
captured by concanavalin A-biotin linked to streptavidin-conjugated magnetic beads before elution, 
HA-directed immunoprecipitation and [3H]ketanserin binding to the 5-HT2AR. Significantly greater 
specific [3H]ketanserin binding (*p<0.05, Wilcoxon test) was found compared to non-immune IgG 
controls in the plasma membrane but not the non-plasma membrane fractions (n=5). Compared to the 
total specific binding recovered from a control solubilisation and capture procedure on unfractionated 
membranes (903 ± 98 dpm per assay), mean specific binding to HA-directed immunoprecipitates and 
non-immune controls represented 37.8% and 14.5% respectively for the plasma membrane fraction 
and 25.1% and 16.1% for the non-plasma membrane flow through. Non-specific binding fell within the 
range 240-310 dpm per assay. (c) GST-fusion proteins of 5-HT2AR domains were captured on 
glutathione-sepharose and incubated with lysates from COS7 cells transfected with HA-PLD1.  A 
typical blot is shown, with input levels of GST constructs (GST-5-HT2ARct(376-471), 40 kDa; GST-5-
HT2ARct(385-471), 39 kDa; GST-5-HT2ARi3(258-326), 36 kDa, GST alone, 29 kDa) displayed in the 
lower panel.  Binding of HA-PLD1 to each of the GST constructs is shown in the upper panel, with the 
most robust interactions occurring with the 5-HT2ARct(385-471) construct.  Minimal interaction was 
detected between PLD1 and GST alone.  The bar chart illustrates results from densitometric analysis 
of results from the similar blots Significant increases in partner protein binding compared to their 
association with the GST-5-HT2ARct(376-471) construct are shown ( *p < 0.05, Wilcoxon test, n = 5 - 
6). 
 
Figure 3   Identification of regions in the 5-HT2ARct important for interactions with PLD1  
GST-fusion proteins of the full length 5-HT2ARct domain (376-471) and three carboxy-terminally 
truncated constructs (376-470), (376-438) and (376-428) were examined for interactions with HA-
PLD1 and ARF1-HA from enriched cell lysates. A representative blot is shown alongside 
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corresponding bar charts produced from densitometric analysis of 5 experiments.  Both HA-PLD1 and 
ARF1-HA associated with the full-length ct construct (376-471).  Removal of residue 471 (i.e. the 376-
470 construct) resulted in a small reduction in the level of HA-PLD1 bound and larger reductions were 
detected upon further ct truncation, as shown with the (376-438) and (376-428) constructs.  In 
contrast, no differences in ARF1-HA association were apparent between the full length and the 
truncated carboxy-terminal constructs (✝p < 0.05, Wilcoxon test; n=5).  
 
Figure 4   HA-PLD1 and ARF1-HA associate separately with the GST-5-HT2ARct   
Aliquots of the full length GST-5-HT2ARct(376-471) construct were captured on glutathione-sepharose 
and subjected to two 12 h incubations with combinations of lysates from cells transfected with ARF1-
HA or HA-PLD1, and the corresponding lysis buffers as indicated.  Input levels of GST-5-HT2ARct(376-
471) are shown in the lower panel. In the left panels the level of HA-PLD1 associated with the 5-
HT2ARct construct appeared to be unaffected following a second incubation period with either ARF1-
HA lysate or ARF lysis buffer.  Conversely, the degree of ARF1-HA interaction with the 5-
HT2ARct(376-471) construct was not changed by the prior association of HA-PLD1 with the construct. 
Similarly, in the right panels the ARF1-HA and GST-5-HT2ARct(376-471) interaction was neither 
altered by, nor altered the subsequent association of HA-PLD1 with the receptor construct.  
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